Related Experiment Videos
Anticancer effects of CAMEL peptide
Ryszard Smolarczyk1, Tomasz Cichoń, Wojciech Kamysz
1Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland. rsmolarczyk@io.gliwice.pl
Summary
Antimicrobial peptide CAMEL shows anticancer effects by inducing cell death and inhibiting melanoma tumor growth. Combination therapy with CAMEL and interleukin-12 gene therapy achieved complete tumor regression in 60% of cases.
Area of Science:
- Biochemistry
- Molecular Biology
- Immunology
Background:
- Antimicrobial peptides (AMPs) are being explored for therapeutic potential beyond infection control.
- The specific AMP, CAMEL (KWKLFKKIGAVLKVL), was investigated for its anticancer properties.
- Understanding the mechanism of action and therapeutic efficacy is crucial for novel cancer treatments.
Purpose of the Study:
- To evaluate the anticancer benefits of the antimicrobial peptide CAMEL.
- To investigate the mechanism by which CAMEL exerts its cytotoxic effects on cancer cells.
- To assess the efficacy of CAMEL, alone and in combination therapy, against melanoma tumor growth.
Main Methods:
- Cytotoxicity assays on various cell lines.
- Hemolysis assays to assess membrane damage.
- Mitochondrial potential assessment and ATP level measurement.
- In vivo studies using B16-F10 melanoma tumor models.
- Combination therapy with CAMEL and interleukin-12 (IL-12) gene therapy.
Main Results:
- CAMEL demonstrated cytotoxicity against tested cell lines without causing hemolysis.
- CAMEL induced cancer cell death by targeting mitochondria, lowering membrane potential, and decreasing ATP levels.
- CAMEL treatment significantly restrained B16-F10 melanoma tumor growth in vivo.
- Combined therapy of CAMEL and IL-12 gene therapy resulted in complete tumor regression in 60% of cases and prolonged survival.
Conclusions:
- CAMEL exhibits significant anticancer activity through mitochondrial-mediated cell death.
- CAMEL monotherapy provides temporary tumor control, with relapse occurring upon cessation of treatment.
- Combination therapy with CAMEL and IL-12 gene therapy offers a potent strategy for complete tumor regression and prevention of relapse in melanoma.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...